查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2139042

肽類治療藥物研發生產機構（CDMO）市場：依服務、合成技術、規模、應用及最終用戶分類－市場規模、產業趨勢、機會分析及2026-2035年預測

Peptide Therapeutics CDMO Market By Service, Synthesis Technology, Scale, Application, End User - Market Size, Industry Dynamics, Opportunity Analysis and Forecast For 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 210 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球胜肽類藥物CDMO（研發生產機構）市場正經歷強勁且持續的成長，這主要得益於代謝性疾病、腫瘤和罕見疾病領域對胜肽類藥物需求的不斷成長。預計到2025年，該市場規模約為45億美元，並預計在2035年達到近200億美元，2026年至2035年預測期內的複合年成長率（CAGR）為16.2%。這一顯著成長反映了越來越多的胜肽類藥物進入臨床開發和商業化階段，以及製藥和生物技術公司對專業外部生產合作夥伴日益成長的依賴。

市場擴張最重要的促進因素之一是代謝療法的快速成長，尤其是Glucagon-Like Peptide-1(GLP-1) 受體促效劑和相關的腸促胰島素療法。針對肥胖症和第2型糖尿病藥物的需求不斷成長，顯著提升了對胜肽類活性成分 (API) 的需求。隨著療法療效的驗證和更廣泛的商業應用，製藥公司需要具備可擴展的合成、純化、分析測試、製劑和生產能力。擁有專業胜肽類基礎設施的合約研發生產機構 (CDMO) 可以提供額外的產能和技術專長，使委託公司能夠在不完全依賴內部生產設施的情況下滿足不斷成長的市場需求。

顯著的市場趨勢

肽類藥物CDMO市場競爭異常激烈，專業胜肽類藥物生產商與一體化合約研發生產機構（CDMO）之間的競爭尤為突出。領先企業正不斷擴大產能、投資先進的合成和純化技術，並強化其全球生產網路，以滿足日益成長的複雜肽類藥物需求。它們的競爭策略日益側重於商業化生產、技術專長、法規遵循能力、供應鏈可靠性以及為製藥客戶提供從早期研發到大規模生產的支援能力。

縱觀競爭格局，各大肽類藥物CDMO廠商正採取不同的策略來滿足日益成長的市場需求。 Bachem公司專注於專業胜肽類藥物的生產和大規模產能擴張，而PolyPeptide Group則專注於建立專屬的胜肽類藥物生產網路。 CordenPharma公司憑藉其更廣泛的端到端藥物生產能力​​脫穎而出，而藥明康德則將肽類藥物的專業技術與一體化的CRDMO模式和不斷擴展的全球基礎設施相結合。 AmbioPharm公司則強調大規模生產，並依託其遍佈美國和亞洲的生產網路。

此外，市場正朝著研發與商業化生產高度整合的方向發展。製藥公司越來越傾向於尋求能夠支持從早期胜肽類藥物研發到臨床供應和商業化生產等全流程專案的CDMO合作夥伴，從​​而降低跨多個供應商進行製程轉移的複雜性。因此，預計對擴大產能、自動化、純化技術、分析基礎設施以及地理分散的生產網路的投資，仍將是胜肽類藥物CDMO市場主要參與企業競爭策略的核心。

主要成長要素

基於GLP-1的療法的快速發展是胜肽類療法合約開發與生產（CDMO）市場成長的主要驅動力。 GLP-1受體促效劑在第2型糖尿病和肥胖症治療的應用日益廣泛，顯著提升了對胜肽類活性成分（API）、製劑服務、分析檢測和大規模生產能力的需求。隨著這些療法從臨床開發階段走向廣泛的商業應用，製藥公司面臨更高的生產需求，為擁有胜肽生產專業知識的CDMO創造了更多商機。

新機會的趨勢

人工智慧驅動的設計範式正成為胜肽類藥物市場的重要機遇，人工智慧在胜肽類藥物發現、分子設計、序列最佳化和臨床前開發等領域的應用日益廣泛。以人工智慧為基礎的平台能夠分析大規模生物和化學資料集，識別序列模式，預測分子行為，並輔助設計具有潛在更佳治療特性的候選胜肽。這些技術減少了對純粹試驗誤法的依賴，幫助研究人員在早期開發階段評估更多候選分子。

最佳化障礙

高昂的生產和純化成本可能成為胜肽治療藥物CDMO市場成長的主要限制因素。治療性胜肽的生產通常需要專用合成設備、高品質的原料、可控的生產環境、先進的分析系統以及技術精湛的技師。與較簡單的藥物生產流程相比，胜肽類藥物的生產涉及眾多合成和純化步驟，導致整體處理時間、資源消耗和營運成本的增加。隨著生產商從實驗室或臨床規模的生產轉向大規模的商業化批量生產，這些成本因素可能變得尤為重要。

目錄

第1章：執行摘要

  • 全球胜肽類治療藥物開發與生產組織（CDMO）市場

第2章：調查方法與研究框架

  • 研究目標
  • 產品概述
  • 市場區隔
  • 定性研究
    • 主要訊息
    • 次要訊息
  • 量化研究
    • 主要訊息
    • 次要訊息
  • 主要調查受訪者組成：按地區分類
  • 本研究的前提
  • 市場規模估算
  • 數據三角測量

第3章：全球胜肽類治療藥物開發與生產組織（CDMO）市場概述

  • 產業價值鏈分析
  • 產業展望
    • 全球胜肽類治療藥物CDMO產業概覽
    • GLP-1腸促胰島素的蓬勃發展帶動了外包業務的激增，因為對胜肽類原料藥的需求量激增至數噸。
    • SPPS連續流方法/自動化採用環保溶劑，複雜的製劑形式（PDC、脂化、口服胜肽），無菌填充和表面處理工程的瓶頸，以及由於資本投資導致的生產能力競爭（Bachem、三星-多肽、CordenPharma）
  • PESTLE分析
  • 波特五力分析
  • 市場成長及前景
    • 2020-2035年市場收入估算與預測
    • 價格趨勢分析：按服務

第4章：全球胜肽類治療藥物研發生產機構（CDMO）市場分析

  • 競爭對手儀錶板
    • 市場集中度
    • 企業市場占有率分析，2025 年
    • 競爭對手分析與基準測試

第5章：全球胜肽類治療藥物研發生產機構（CDMO）市場分析

  • 市場動態和趨勢
    • 成長要素
    • 抑制因子
    • 機會
    • 主要趨勢
  • 市場規模及預測，2020-2035年
    • 按服務
      • 關鍵見解
        • 胜肽類原料藥生產
        • 藥品準備/灌裝和包裝
        • 製程開發
        • 分析/品管（QC）
    • 透過合成技術
      • 關鍵見解
        • 固相胜肽合成
        • 液相胜肽合成
        • 雜交/重組
        • 連續流
    • 按尺寸
      • 關鍵見解
        • 臨床前和臨床
        • 商業的
    • 透過使用
      • 關鍵見解
        • 代謝/GLP-1
        • 腫瘤學
        • 感染疾病
        • 罕見疾病
        • 化妝品
        • 其他
    • 最終用戶
      • 關鍵見解
        • 大型製藥企業
        • 新興生物製藥
        • 學名藥生產商
    • 按地區
      • 關鍵見解
        • 北美洲
          • 美國
          • 加拿大
          • 墨西哥
        • 歐洲
          • 西歐
            • 英國
            • 德國
            • 法國
            • 義大利
            • 西班牙
            • 其他西歐國家
          • 東歐
            • 波蘭
            • 俄羅斯
            • 其他東歐國家
        • 亞太地區
          • 中國
          • 印度
          • 日本
          • 澳洲和紐西蘭
          • 韓國
          • ASEAN
          • 其他亞太國家
        • 中東和非洲（MEA）
          • 沙烏地阿拉伯
          • 南非
          • UAE
          • 其他中東和非洲國家
        • 南美洲
          • 阿根廷
          • 巴西
          • 其他南美國家

第6章：北美市場分析

第7章：歐洲市場分析

第8章：亞太市場分析

第9章：中東和非洲市場分析

第10章：南美市場分析

第11章：公司簡介

公司簡介（公司概況、財務指標、主要產品清單、主要負責人、主要競爭對手、聯絡資訊和業務策略展望）

  • Bachem
  • PolyPeptide Group
  • Lonza
  • Thermo Fisher Scientific (Patheon)
  • WuXi AppTec (WuXi TIDES)
  • CordenPharma
  • Almac Group
  • Piramal Pharma Solutions
  • Evonik
  • Hovione
  • Fresenius Kabi
  • Ambiopharm
  • ScinoPharm
  • Peptide Institute
  • Sai Life Sciences
  • 其他主要公司

第12章附錄

簡介目錄
Product Code: AA09261985

The global peptide therapeutics contract development and manufacturing organization (CDMO) market is experiencing strong and sustained expansion, supported by increasing demand for peptide-based medicines across metabolic disorders, oncology, and rare diseases. The market is estimated at approximately USD 4.5 billion in 2025 and is projected to reach nearly USD 20 billion by 2035, representing a compound annual growth rate (CAGR) of 16.2% during the 2026-2035 forecast period. This substantial increase reflects the growing number of peptide therapeutics progressing through clinical development and commercialization, as well as the increasing reliance of pharmaceutical and biotechnology companies on specialized external manufacturing partners.

One of the most significant contributors to market expansion is the rapid growth of metabolic therapies, particularly glucagon-like peptide-1 (GLP-1) receptor agonists and related incretin-based treatments. Rising demand for medicines targeting obesity and type 2 diabetes is creating requirements for substantially larger quantities of peptide active pharmaceutical ingredients (APIs). As successful therapies move into broader commercial use, pharmaceutical companies need scalable synthesis, purification, analytical testing, formulation, and manufacturing capabilities. CDMOs with specialized peptide infrastructure can provide additional capacity and technical expertise, allowing sponsors to respond to increasing market demand without relying exclusively on internal manufacturing facilities.

Noteworthy Market Developments

The peptide therapeutics CDMO market is characterized by strong competition among specialized peptide manufacturers and integrated contract development and manufacturing organizations. Leading companies are expanding their production capacity, investing in advanced synthesis and purification technologies, and strengthening their global manufacturing networks to accommodate increasing demand for complex peptide therapeutics. Their competitive strategies increasingly focus on commercial-scale production, technical expertise, regulatory capabilities, supply-chain reliability, and the ability to support pharmaceutical customers from early development through large-scale manufacturing.

The competitive landscape demonstrates that leading peptide therapeutics CDMOs are pursuing different strategies to capture growing demand. Bachem emphasizes specialized peptide manufacturing and significant capacity expansion, while PolyPeptide Group focuses on its dedicated peptide manufacturing network. CordenPharma differentiates itself through broader end-to-end pharmaceutical manufacturing capabilities, and WuXi TIDES combines peptide specialization with an integrated CRDMO model and expanding global infrastructure. AmbioPharm emphasizes large-scale manufacturing supported by a geographically diversified U.S.-Asia production network.

The market is also moving toward greater integration between development and commercial manufacturing. Pharmaceutical sponsors increasingly seek CDMO partners that can support projects from early-stage peptide development through clinical supply and commercial-scale production, reducing the complexity associated with transferring processes between multiple suppliers. As a result, investments in capacity expansion, automation, purification technologies, analytical infrastructure, and geographically diversified manufacturing networks are expected to remain central to the competitive strategies of major participants in the peptide therapeutics CDMO market.

Core Growth Drivers

The rapid expansion of GLP-1-based therapies has become a major factor supporting growth in the peptide therapeutics contract development and manufacturing organization (CDMO) market. Increasing adoption of GLP-1 receptor agonists for the treatment of type 2 diabetes and obesity has created substantial demand for peptide active pharmaceutical ingredients (APIs), formulation services, analytical testing, and large-scale manufacturing capacity. As these therapies move from clinical development into broad commercial use, pharmaceutical companies are facing significantly higher production requirements, creating additional opportunities for specialized CDMOs with peptide manufacturing expertise.

Emerging Opportunity Trends

AI-driven design paradigms are emerging as an important opportunity within the peptide therapeutics market, with artificial intelligence increasingly being applied to peptide discovery, molecular design, sequence optimization, and preclinical development. AI-based platforms can analyze large biological and chemical datasets to identify sequence patterns, predict molecular behavior, and support the design of peptide candidates with potentially improved therapeutic characteristics. By reducing the dependence on purely trial-and-error approaches, these technologies can help researchers evaluate a larger number of candidate molecules during the early stages of development.

Barriers to Optimization

High manufacturing and purification costs may act as a significant constraint on the growth of the peptide therapeutics CDMO market. The production of therapeutic peptides often requires specialized synthesis equipment, high-quality raw materials, controlled manufacturing environments, advanced analytical systems, and highly skilled technical personnel. Compared with less complex pharmaceutical manufacturing processes, peptide production can involve numerous synthesis and purification steps, increasing overall processing time, resource consumption, and operational expenditure. These cost considerations can become particularly significant as manufacturers move from laboratory and clinical-scale production to larger commercial batches.

Detailed Market Segmentation

By synthesis technology, Solid-Phase Peptide Synthesis (SPPS) represents a major manufacturing approach within the peptide therapeutics CDMO market in 2026. The technology has become widely established for the production of therapeutic peptides because it provides a flexible and scalable platform for assembling amino acid sequences while supporting precise control over individual synthesis steps. Its compatibility with automation, established process-development methodologies, and ability to accommodate increasingly complex peptide structures have contributed to its continued adoption among pharmaceutical companies and specialized CDMOs.

By scale, commercial-scale manufacturing represents a major revenue-generating segment within the peptide therapeutics contract development and manufacturing organization (CDMO) market. The expansion of peptide-based medicines into large commercial markets is increasing demand for high-volume production capabilities, particularly as successful therapies transition from clinical development to routine commercial supply. Once a peptide therapeutic achieves broad market adoption, manufacturing requirements can increase substantially, creating sustained demand for CDMOs with the infrastructure, technical expertise, and regulatory capabilities required to support large-scale production.

By application, metabolic and GLP-1 therapies represent a major demand driver within the peptide therapeutics contract development and manufacturing organization (CDMO) market in 2026. The rapid development and commercialization of incretin-based medicines for metabolic disorders, particularly obesity and type 2 diabetes, have significantly increased demand for peptide synthesis, purification, formulation, analytical testing, and commercial manufacturing services. The expansion of these therapies has created substantial requirements for production capacity, encouraging pharmaceutical companies and biotechnology developers to work with specialized CDMOs to supplement internal manufacturing capabilities.

By end user, large pharmaceutical companies represent a major source of demand within the peptide therapeutics contract development and manufacturing organization (CDMO) market. These companies manage extensive portfolios of branded and generic medicines, including an increasing number of peptide-based therapies that require specialized development and manufacturing capabilities. Although large pharmaceutical organizations typically maintain substantial internal research, development, and manufacturing infrastructure, the growing complexity and volume requirements associated with peptide therapeutics are encouraging greater use of external CDMO services.

Segment Breakdown

By Service

  • Peptide API Manufacturing
  • Drug Product/Fill-Finish
  • Process Development
  • Analytical & QC

By Synthesis Technology

  • Solid-Phase Peptide Synthesis
  • Liquid-Phase Peptide Synthesis
  • Hybrid/Recombinant
  • Continuous Flow

By Scale

  • Preclinical & Clinical
  • Commercial

By Application

  • Metabolic/GLP-1
  • Oncology
  • Infectious Disease
  • Rare Disease
  • Cosmetic
  • Others

By End User

  • Large Pharma
  • Emerging Biopharma
  • Generic Manufacturers

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America
  • Geography Analysis
  • North America holds a leading position in the peptide therapeutics contract development and manufacturing organization (CDMO) market, with the United States and Canada serving as major contributors to regional growth. The region benefits from a highly developed pharmaceutical and biotechnology ecosystem, substantial investment in drug discovery and development, advanced manufacturing capabilities, and the presence of established CDMO providers.
  • The United States represents the principal contributor to the regional market, accounting for more than 85% of North American revenue in 2026 according to the stated market estimates. Its strong market position is supported by the concentration of pharmaceutical companies, biotechnology firms, research institutions, and specialized manufacturing organizations across the country.
  • Canada also contributes to the broader North American peptide therapeutics manufacturing ecosystem through its pharmaceutical research capabilities, biotechnology sector, specialized manufacturing organizations, and connections with the U.S. market. Canadian companies and research institutions participate in drug discovery, development, clinical research, and pharmaceutical manufacturing activities, creating additional opportunities for CDMOs and related service providers.

Leading Market Participants

  • Bachem
  • PolyPeptide Group
  • Lonza
  • Thermo Fisher Scientific (Patheon)
  • WuXi AppTec (WuXi TIDES)
  • CordenPharma
  • Almac Group
  • Piramal Pharma Solutions
  • Evonik
  • Hovione
  • Fresenius Kabi
  • Ambiopharm
  • ScinoPharm
  • Peptide Institute
  • Sai Life Sciences
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary

  • 1.1. Global Peptide Therapeutics CDMO Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary Sources
    • 2.4.2. Secondary Sources
  • 2.5. Quantitative Research
    • 2.5.1. Primary Sources
    • 2.5.2. Secondary Sources
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global Peptide Therapeutics CDMO Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Amino-Acid/Resin & Specialty-Reagent Suppliers
    • 3.1.2. Peptide API Synthesis (SPPS, LPPS, Hybrid) CDMOs
    • 3.1.3. Drug-Product Fill-Finish, Device-Assembly & Lyophilization Providers
    • 3.1.4. Process-Development, Analytical/QC & Regulatory-Compliance Partners
    • 3.1.5. End Users (Large Pharma, Emerging Biopharma, Generic Manufacturers)
  • 3.2. Industry Outlook
    • 3.2.1. Overview of the Global Peptide Therapeutics CDMO Industry
    • 3.2.2. GLP-1 Incretin Boom Driving Metric-Ton Peptide API Demand & Outsourcing Surge
    • 3.2.3. SPPS Continuous-Flow / Greener-Solvent Automation, Complex Modalities (PDCs, Lipidation, Oral Peptides), Sterile Fill-Finish Bottleneck & CapEx Capacity Race (Bachem, Samsung-PolyPeptide, CordenPharma)
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of New Entrants
    • 3.4.4. Threat of Substitutes
    • 3.4.5. Intensity of Rivalry
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Price Trend Analysis, By Service

Chapter 4. Global Peptide Therapeutics CDMO Market Analysis

  • 4.1. Competition Dashboard
    • 4.1.1. Market Concentration Rate
    • 4.1.2. Company Market Share Analysis (Value %), 2025
    • 4.1.3. Competitor Mapping & Benchmarking

Chapter 5. Global Peptide Therapeutics CDMO Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Service
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Peptide API Manufacturing
        • 5.2.1.1.2. Drug Product/Fill-Finish
        • 5.2.1.1.3. Process Development
        • 5.2.1.1.4. Analytical & QC
    • 5.2.2. By Synthesis Technology
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Solid-Phase Peptide Synthesis
        • 5.2.2.1.2. Liquid-Phase Peptide Synthesis
        • 5.2.2.1.3. Hybrid/Recombinant
        • 5.2.2.1.4. Continuous Flow
    • 5.2.3. By Scale
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Preclinical & Clinical
        • 5.2.3.1.2. Commercial
    • 5.2.4. By Application
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. Metabolic/GLP-1
        • 5.2.4.1.2. Oncology
        • 5.2.4.1.3. Infectious Disease
        • 5.2.4.1.4. Rare Disease
        • 5.2.4.1.5. Cosmetic
        • 5.2.4.1.6. Others
    • 5.2.5. By End User
      • 5.2.5.1. Key Insights
        • 5.2.5.1.1. Large Pharma
        • 5.2.5.1.2. Emerging Biopharma
        • 5.2.5.1.3. Generic Manufacturers
    • 5.2.6. By Region
      • 5.2.6.1. Key Insights
        • 5.2.6.1.1. North America
          • 5.2.6.1.1.1. The U.S.
          • 5.2.6.1.1.2. Canada
          • 5.2.6.1.1.3. Mexico
        • 5.2.6.1.2. Europe
          • 5.2.6.1.2.1. Western Europe
            • 5.2.6.1.2.1.1. The UK
            • 5.2.6.1.2.1.2. Germany
            • 5.2.6.1.2.1.3. France
            • 5.2.6.1.2.1.4. Italy
            • 5.2.6.1.2.1.5. Spain
            • 5.2.6.1.2.1.6. Rest of Western Europe
          • 5.2.6.1.2.2. Eastern Europe
            • 5.2.6.1.2.2.1. Poland
            • 5.2.6.1.2.2.2. Russia
            • 5.2.6.1.2.2.3. Rest of Eastern Europe
        • 5.2.6.1.3. Asia Pacific
          • 5.2.6.1.3.1. China
          • 5.2.6.1.3.2. India
          • 5.2.6.1.3.3. Japan
          • 5.2.6.1.3.4. Australia & New Zealand
          • 5.2.6.1.3.5. South Korea
          • 5.2.6.1.3.6. ASEAN
          • 5.2.6.1.3.7. Rest of Asia Pacific
        • 5.2.6.1.4. Middle East & Africa (MEA)
          • 5.2.6.1.4.1. Saudi Arabia
          • 5.2.6.1.4.2. South Africa
          • 5.2.6.1.4.3. UAE
          • 5.2.6.1.4.4. Rest of MEA
        • 5.2.6.1.5. South America
          • 5.2.6.1.5.1. Argentina
          • 5.2.6.1.5.2. Brazil
          • 5.2.6.1.5.3. Rest of South America

Chapter 6. North America Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. Key Insights
      • 6.2.1.1. By Service
      • 6.2.1.2. By Synthesis Technology
      • 6.2.1.3. By Scale
      • 6.2.1.4. By Application
      • 6.2.1.5. By End User
      • 6.2.1.6. By Country

Chapter 7. Europe Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. Key Insights
      • 7.2.1.1. By Service
      • 7.2.1.2. By Synthesis Technology
      • 7.2.1.3. By Scale
      • 7.2.1.4. By Application
      • 7.2.1.5. By End User
      • 7.2.1.6. By Country

Chapter 8. Asia Pacific Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. Key Insights
      • 8.2.1.1. By Service
      • 8.2.1.2. By Synthesis Technology
      • 8.2.1.3. By Scale
      • 8.2.1.4. By Application
      • 8.2.1.5. By End User
      • 8.2.1.6. By Country

Chapter 9. Middle East & Africa (MEA) Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. Key Insights
      • 9.2.1.1. By Service
      • 9.2.1.2. By Synthesis Technology
      • 9.2.1.3. By Scale
      • 9.2.1.4. By Application
      • 9.2.1.5. By End User
      • 9.2.1.6. By Country

Chapter 10. South America Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. Key Insights
      • 10.2.1.1. By Service
      • 10.2.1.2. By Synthesis Technology
      • 10.2.1.3. By Scale
      • 10.2.1.4. By Application
      • 10.2.1.5. By End User
      • 10.2.1.6. By Country

Chapter 11. Company Profile

Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. Bachem
  • 11.2. PolyPeptide Group
  • 11.3. Lonza
  • 11.4. Thermo Fisher Scientific (Patheon)
  • 11.5. WuXi AppTec (WuXi TIDES)
  • 11.6. CordenPharma
  • 11.7. Almac Group
  • 11.8. Piramal Pharma Solutions
  • 11.9. Evonik
  • 11.10. Hovione
  • 11.11. Fresenius Kabi
  • 11.12. Ambiopharm
  • 11.13. ScinoPharm
  • 11.14. Peptide Institute
  • 11.15. Sai Life Sciences
  • 11.16. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators